We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
REGN Soars 28.9% in Six Months: Is There More Upside Potential in 2026?
Read MoreHide Full Article
Key Takeaways
Regeneron shares surged 31.5% in six months, driven by pipeline progress and strong earnings.
Dupixent growth and label expansions boost revenues, while Eylea faces decline and rising biosimilar pressure.
Oncology and new drugs like Libtayo and Lynozyfic support diversification beyond core franchises.
The going has been strong for Regeneron Pharmaceuticals (REGN - Free Report) over the past six months. Shares of this biotech giant have surged 31.5% in this time frame, outpacing the industry’s growth of 13.5%. The stock has also outperformed the sector and the S&P 500 Index during this time.
REGN’s robust rally has been driven by a series of positive pipeline and regulatory developments and better-than-expected quarterly results, which have improved investor sentiment.
REGN Outperforms Industry, Sector and S&P 500 Index
Image Source: Zacks Investment Research
Against this backdrop, a closer evaluation of the company’s strengths and weaknesses can help assess its attractiveness as an investment opportunity.
REGN’s Eylea HD Gains Traction as Eylea Sales Decline
While lead drug Eylea continues to face headwinds, Eylea HD is gaining traction, supported by steady label expansions.
Eylea, an anti-VEGF therapy approved across multiple ophthalmology indications, remains Regeneron’s largest revenue contributor. Declining franchise sales continue to pressure the company’s overall revenues.
Competitive pressure has intensified, particularly from Roche’s (RHHBY - Free Report) Vabysmo, which targets both angiopoietin-2 (Ang-2) and VEGF-A pathways and has gained meaningful traction in the retinal disease market.
RHHBY’s Vabysmo’s sales grew 12% to CHF 4.1 billion in 2025 on strong demand across all regions.
To defend market share, Regeneron introduced Eylea HD, a higher-dose formulation designed to improve durability and extend dosing intervals.
Eylea HD sales rose 36% in 2025 to $1.6 billion in the United States.
In November 2025, the FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion (RVO), with dosing of up to once every eight weeks after an initial monthly dosing phase. The FDA also approved a monthly dosing option for certain patients who may benefit from resuming this dosing schedule across all currently approved indications, including wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy and RVO.
Eylea and Eylea HD were co-developed with Bayer (BAYRY - Free Report) .
Regeneron records net product sales in the United States, while Bayer records sales outside the country.
Regeneron expects a further decline in Eylea sales in 2026. The anticipated erosion is likely to accelerate in the second half of the year as multiple biosimilar versions enter the U.S. market.
Strong Dupixent Sales Fuel REGN Profits
REGN’s top line also comprises its share of profits/losses in connection with the global sales of Dupixent. Partner Sanofi (SNY - Free Report) records global net product sales of Dupixent.
Strong demand across approved indications — including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis and eosinophilic esophagitis — continues to drive robust growth. Ongoing label expansions for Dupixent remain a key contributor to revenue visibility and profitability.
Last month, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) backed approval of Dupixent (dupilumab) in the EU for children aged 2–11 with moderate-to-severe chronic spontaneous urticaria who have an inadequate response to antihistamines and are IgE therapy-naïve. A final decision is expected soon.
The FDA recently approved Dupixent for patients aged six and older with allergic fungal rhinosinusitis (AFRS) who have undergone sino-nasal surgery. The approval expands Dupixent’s sino-nasal indications to include AFRS alongside chronic rhinosinusitis with nasal polyps.
Regeneron Expands and Strengthens Its Oncology Portfolio
Regeneron’s oncology franchise is anchored by its PD-1 inhibitor Libtayo (cemiplimab-rwlc), which is approved for use in certain patients with advanced basal cell carcinoma (BCC), advanced cutaneous squamous cell carcinoma (CSCC) and advanced non-small cell lung cancer (NSCLC).
Libtayo delivered a solid performance in 2025, generating $1.4 billion in sales, which reflects a 19% year-over-year increase. Regeneron records global net product sales of Libtayo and pays royalties to partner Sanofi on these sales.
The oncology portfolio received an additional boost with the FDA’s accelerated approval of linvoseltamab-gcpt for the treatment of relapsed or refractory multiple myeloma under the brand name Lynozyfic. The drug is also approved in the European Union for adults with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.
Further strengthening the franchise, the EC approved Ordspono (odronextamab) for the treatment of adult patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma following two or more lines of systemic therapy. Regeneron also has a deep pipeline of promising candidates, and additional drug approvals are expected to support the top line.
REGN: Valuation & Estimates
Going by the price/earnings ratio, REGN seems failry priced at this moment. Shares currently trade at 16.39X forward earnings, lower than its mean of 19.42X and the large-cap pharma industry’s value of 16.75X.
Image Source: Zacks Investment Research
The bottom-line estimate for 2026 has moved north over the past 60 days and the same for 2027 has increased $2.22.
Image Source: Zacks Investment Research
Stay Invested in Regeneron
REGN is one of the largest biotechs in the sector that are considered safe havens for investors interested in this sector.
Progress across its oncology portfolio should support greater diversification of revenues and reduce reliance on any single franchise.
Ongoing label expansions for Dupixent continue to drive strong sales growth and contribute meaningfully to profitability. At the same time, the launch of Eylea HD is helping Regeneron mitigate the impact of declining sales of the Eylea amid rising competition.
While the recent pipeline momentum and favorable regulatory developments have improved the outlook, declining Eylea sales are a major headwind. Given that Eylea contributes a substantial portion of Regeneron’s overall sales, the competitive impact has weighed on the company’s top-line performance.
Hence, we advise prospective investors to wait and observe for a while before turning positive. Investors already holding the stock may find it prudent to stay invested.
View the Zacks #1 Rank List
Image: Bigstock
REGN Soars 28.9% in Six Months: Is There More Upside Potential in 2026?
Key Takeaways
The going has been strong for Regeneron Pharmaceuticals (REGN - Free Report) over the past six months. Shares of this biotech giant have surged 31.5% in this time frame, outpacing the industry’s growth of 13.5%. The stock has also outperformed the sector and the S&P 500 Index during this time.
REGN’s robust rally has been driven by a series of positive pipeline and regulatory developments and better-than-expected quarterly results, which have improved investor sentiment.
REGN Outperforms Industry, Sector and S&P 500 Index
Image Source: Zacks Investment Research
Against this backdrop, a closer evaluation of the company’s strengths and weaknesses can help assess its attractiveness as an investment opportunity.
REGN’s Eylea HD Gains Traction as Eylea Sales Decline
While lead drug Eylea continues to face headwinds, Eylea HD is gaining traction, supported by steady label expansions.
Eylea, an anti-VEGF therapy approved across multiple ophthalmology indications, remains Regeneron’s largest revenue contributor. Declining franchise sales continue to pressure the company’s overall revenues.
Competitive pressure has intensified, particularly from Roche’s (RHHBY - Free Report) Vabysmo, which targets both angiopoietin-2 (Ang-2) and VEGF-A pathways and has gained meaningful traction in the retinal disease market.
RHHBY’s Vabysmo’s sales grew 12% to CHF 4.1 billion in 2025 on strong demand across all regions.
To defend market share, Regeneron introduced Eylea HD, a higher-dose formulation designed to improve durability and extend dosing intervals.
Eylea HD sales rose 36% in 2025 to $1.6 billion in the United States.
In November 2025, the FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion (RVO), with dosing of up to once every eight weeks after an initial monthly dosing phase. The FDA also approved a monthly dosing option for certain patients who may benefit from resuming this dosing schedule across all currently approved indications, including wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy and RVO.
Eylea and Eylea HD were co-developed with Bayer (BAYRY - Free Report) .
Regeneron records net product sales in the United States, while Bayer records sales outside the country.
Regeneron expects a further decline in Eylea sales in 2026. The anticipated erosion is likely to accelerate in the second half of the year as multiple biosimilar versions enter the U.S. market.
Strong Dupixent Sales Fuel REGN Profits
REGN’s top line also comprises its share of profits/losses in connection with the global sales of Dupixent. Partner Sanofi (SNY - Free Report) records global net product sales of Dupixent.
Strong demand across approved indications — including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis and eosinophilic esophagitis — continues to drive robust growth. Ongoing label expansions for Dupixent remain a key contributor to revenue visibility and profitability.
Last month, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) backed approval of Dupixent (dupilumab) in the EU for children aged 2–11 with moderate-to-severe chronic spontaneous urticaria who have an inadequate response to antihistamines and are IgE therapy-naïve. A final decision is expected soon.
The FDA recently approved Dupixent for patients aged six and older with allergic fungal rhinosinusitis (AFRS) who have undergone sino-nasal surgery. The approval expands Dupixent’s sino-nasal indications to include AFRS alongside chronic rhinosinusitis with nasal polyps.
Regeneron Expands and Strengthens Its Oncology Portfolio
Regeneron’s oncology franchise is anchored by its PD-1 inhibitor Libtayo (cemiplimab-rwlc), which is approved for use in certain patients with advanced basal cell carcinoma (BCC), advanced cutaneous squamous cell carcinoma (CSCC) and advanced non-small cell lung cancer (NSCLC).
Libtayo delivered a solid performance in 2025, generating $1.4 billion in sales, which reflects a 19% year-over-year increase. Regeneron records global net product sales of Libtayo and pays royalties to partner Sanofi on these sales.
The oncology portfolio received an additional boost with the FDA’s accelerated approval of linvoseltamab-gcpt for the treatment of relapsed or refractory multiple myeloma under the brand name Lynozyfic. The drug is also approved in the European Union for adults with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.
Further strengthening the franchise, the EC approved Ordspono (odronextamab) for the treatment of adult patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma following two or more lines of systemic therapy.
Regeneron also has a deep pipeline of promising candidates, and additional drug approvals are expected to support the top line.
REGN: Valuation & Estimates
Going by the price/earnings ratio, REGN seems failry priced at this moment. Shares currently trade at 16.39X forward earnings, lower than its mean of 19.42X and the large-cap pharma industry’s value of 16.75X.
Image Source: Zacks Investment Research
The bottom-line estimate for 2026 has moved north over the past 60 days and the same for 2027 has increased $2.22.
Image Source: Zacks Investment Research
Stay Invested in Regeneron
REGN is one of the largest biotechs in the sector that are considered safe havens for investors interested in this sector.
Progress across its oncology portfolio should support greater diversification of revenues and reduce reliance on any single franchise.
Ongoing label expansions for Dupixent continue to drive strong sales growth and contribute meaningfully to profitability. At the same time, the launch of Eylea HD is helping Regeneron mitigate the impact of declining sales of the Eylea amid rising competition.
While the recent pipeline momentum and favorable regulatory developments have improved the outlook, declining Eylea sales are a major headwind. Given that Eylea contributes a substantial portion of Regeneron’s overall sales, the competitive impact has weighed on the company’s top-line performance.
Hence, we advise prospective investors to wait and observe for a while before turning positive. Investors already holding the stock may find it prudent to stay invested.
REGN currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.